WWTR1 and melanoma: YAP/TAZ-dependent actin cytoskeleton remodeling and cell spreading promote an acquisition of a phenotype resistant against the treatment with the BRAF inhibitor PLX4032 (vemurafenib) in melanoma cells in vitro [128].